List of Vendor Companies in Spain - 34

We are now 3PBIOVIAN! 𝗙𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 𝗼𝗻 𝗼𝘂𝗿 𝗻𝗲𝘄 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗮𝗴𝗲, 𝟯𝗣𝗕𝗜𝗢𝗩𝗜𝗔𝗡, 𝘁𝗼 𝘀𝘁𝗮𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝗱 𝗼𝗻 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗻𝗲𝘄𝘀! 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO. Read more here: www.3pbiovian.com ***** 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Our service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. Additionally, we provide fill and finish services for recombinant proteins and viral vectors. With a combined track record of 40 years in process development and analytical methods development, complemented by our experience in process scale-up, GMP manufacturing, and commercial supply, we are equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Our manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of our clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.

ABANZA specializes in the Development & Research of Innovative Medical Devices in the field of Sports Medicine - Soft Tissue repair. With the goal of offering cutting edge surgical tools, ABANZA is supported by a first class medical advisory team in order to ensure that the devices developed are safe and easy to handle, thereby offering surgeons the utmost reliability and ensuring that patients receive the best possible care.

What started as a small family business in 1988 has since evolved into a global market leader, providing orthopaedic and medical solutions that improve patient care around the world. https://www.acumed.net/products/osteomed-hand-wrist/ Our story begins in Butler, NJ, where Mary and Randy Huebner founded Accurate Machine and Design, also known as Acumed. With only one machinist on staff, Acumed was contracted to engineer implant prototypes for some of the biggest names in the industry. After relocating to Oregon in 1991, we launched our first line of arthroscopy screws intended for ACL ligaments and haven’t looked back since. The successes of the Oregon Fixation Screw allowed Acumed to research, design, and manufacture the majority of our products while adding new lines each year. In 1999, Colson Associates, a division of The Marmon Group, purchased Acumed and provided the capital to purchase new equipment and a new facility to step up our production efforts. Currently Headquartered in Hillsboro, Oregon, with a global distribution network and offices worldwide Acumed is a multi-award-winning company, dedicated to innovative and quality medical device solutions. We are committed to the highest standards of manufacturing and proudly produce over 90% of our implants in the U.S. Throughout our history, Acumed has remained focused on the founders’ original vision of providing innovative solutions to meet the needs of the whole healthcare community, including hospitals, surgeons and patients.

Genetic progress in recent years is only comparable to the advancements in the field of computer science. Our vision is to enable everyone to learn about their unique genetic code and inspire new ideas and scientific approaches. Since the completion of the human genetic code in 2003, the number of studies and sources of information on genetic markers, along with the scientific drive to better understand the genotype-phenotype has grown exponentially. In ADNTRO we help you navigate all present & future findings. Invest in your DNA – its for Life.

AntalGenics is a biotechnological company focused on the design and development of new active molecules for biomedical and dermocosmetic applications MISSION To discover and develop innovative leads in the field of sensory neurobiology with pharmaceutical and dermocosmetical applications. VISION To transform our scientific results into products and services for society and to improve the quality of life.

Bioarray is a genetic testing provider, serving clinical partners in Europe, Latin America, MENA and Asia. Mainly using array CGH and NGS for: - Medical Genetics: WES, WGS - Reproductive Genetics: expanded carrier screening, preimplantation genetic testing (PGT), endometrial receptivity and prenatal diagnosis - Oncology: somatic and germline tests, liquid biopsy Bioarray is also a leading provider of research services, as gene expression studies based on array or RNA-seq. Bioarray's sister company Journey Genomics launched PGD-Seq™, a kit for library preparation and data analysis, for easy PGT-M implementation for NGS labs.

BioBam BioinformaticsoffersBlast2GO a user-friendly solution specially designed for plant and animal research.

BLUEPHAGE S.L. is a biotechnology company specializing in environmental testing solutions and launched as a spinoff company in 2016 from the University of Barcelona, Spain. Using a patent-protected accelerated coliphage indicator test, our microbiological water quality testing products detect bacteriophages as indicators of viruses that cause serious waterborne diseases. Our product pipeline will offer the fastest and easiest to use bacteriophage detection method currently available on the market for environmental testing of water. BLUEPHAGE's team of world renowned experts in basic and applied microbiology and virology in water testing methods tap into 35+ years of knowledge and know-how developed at the University of Barcelona within the MARS research group (Water Microbiology Related to Health).

Highly specialized and customer-oriented, Certest Biotec consists of four divisions, including Raw Materials, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), Molecular Biology under the VIASURE brand, and Pharma. Certest Raw Materials provides high quality solutions for developing and manufacturing your IVD assays. Our expertise in protein expresión & purification, monoclonal antibodies develoment & manufacturing and primers & probes manufacturing offer to our customers a priceless support in their challenging proyects. Certest Immunodiagnostic -Rapid Test, Turbidimetry, CLIA- is committed to providing a comprehensive portfolio of diagnostic reagents for detecting infectious diseases and different markers, covering different needs of formats, types of use, throughput, precision and time from sample to result. VIASURE offers a reliable molecular diagnostic solution, from sample to intepretation of results, covering a wide range portfolio of products and enabling laboratories to better inform clinical decissions. The objective of Certest Pharma is to contribute with its technology to obtain better therapeutic products based on RNA. It is focused on three main áreas: RNAs, Delivery and Vaccines. Additionally, the expertise of our highly qualified personnel, currently numbering over 300 employees, is at the disposal of our customers, offering development and manufacturing services for the production of their own materials.

The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (Ciberdem) is a public state consortium established by the Carlos III Health Institute (Ministry of Economy and Competitiveness). Constituted by 31 elite research groups in 19 associate institutions, it represents the biggest network of scientific diabetes research in Spain. Its objectives are to lead highest standards of research practice and to accelerate the translation of scientific results into clinical application. Ciberdem looks to involve not only the scientific community but also the business sector in R&D investment. The consortium offers companies the possibility of working together on research projects, scientific consultancy, organisation of scientific events and socially responsible corporate actions. Ciberdem divulges its scientific work through multiple actions such as the periodic organisation of scientific seminars and its annual Science Open Day always with the active collaboration of patient associations. In its mision to promote diabetes research Ciberdem has created «Investiga la diabetes», an initiative which seeks to increase awareness of the diabetes problem in Spain. Its objective is to generate active participation from society and business with the aim of collecting funds which will enable the continued promotion and financing of scientific activity to find new means of preventing, diagnosing, treating and curing diabetes. ciberdem.org investigaladiabetes.org

CUBIQ FOODS | Transforming the future of nutrition We are on a mission to improve nutrition around the world. Everything we do is focused on radically improving sustainability, health and nutritional profile, with affordability in mind. We also prioritize the consumers' organoleptic experience across as many products as possible. As an international food tech company, we combine our scientific knowledge and expertise with the latest advances to provide an innovative range of alternative fats. 
 We lead in three distinct processes; a novel oil/water emulsion, Omega-3 micro-encapsulation techniques, and the first cell-culture platform for specialty fats (cell-based Omega-3).
 Our solutions to the food industry support the development of high-quality processed food. We achieve this by reducing animal and saturated fats while retaining flavor and texture. We deliver health and nutritional benefits and reduce the calorie content. 
 Our innovative platforms can tune for hardness, texture, and flavor as well as fat content in bespoke product applications. 
 We produce and sell at scale and license production to select producers worldwide. Let's change food from the inside!

Curapath is a CDMO with expertise in developing novel drug delivery systems (DDS). What sets us apart is our analytical expertise in the formulation and manufacturing of Lipid nanoparticles (LNP) and Polymer nanoparticles (PNP). When you start working with Curapath, we can support your entire therapeutic journey from development to IND. Curapath supports GMP manufacturing of Drug Substance and Drug Product for clinical trial material. We provided unmatched technical support and analytical expertise in the custom design, development, and end-to-end GMP manufacturing of polymer and lipid-based drug delivery systems to support cell therapy, gene therapy, and vaccine delivery. For over a decade, Curapath has supported drug innovators in developing stealth shielding polymers (polyaminoacids), functional polymer & lipid excipients, linkers for bioconjugation, and API polymers used for therapeutics. Our history of success makes Curapath the right partner to drive your therapeutic development. We deliver consultative hands-on guidance from preclinical development through commercial-scale GMP manufacturing. Curapath is a knowledgeable partner you can trust to move fast, manufacture smart, and provide support through your drug development journey, accelerating your speed to the clinic. We help our partners solve even the most complex drug delivery challenges.

DESTINA Genomics Ltd. is a biotech company founded in Edinburgh in 2011 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley. In July 2012, it was created the Spanish subsidiary DESTINA Genomica S.L. with the goal to accelerate a long-term growth plan. The company is focused on the application and validation of its patented state-of-the-art technologies. DESTINA has created a unique and reliable chemistry for highly specific detection of nucleic acids. It can be used to identify any known target nucleic acid sequence, and in particular can directly detect small RNAs, without the multiple steps required by current methods. DESTINA mission is to become a leading manufacturer and supplier of custom chemical reagents and technologies for ‘best in class' nucleic acid based biomarker assays. DESTINA's technology introduces cheaper, more accurate and much more meaningful Nucleic Acid Testing tools.

next-gen sequencing analytics

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and other innovative biopharmaceutical solutions.

Hospital Sant Joan de Déu (Barcelona) is a teaching hospital specializing in the fields of pediatrics, gynecology and obstetrics. It is located in Barcelona, Catalonia (Spain). It is a privately owned center, concerted by the Catalan Public Health Service, which belongs to the Hospitaller Order of St. John of God, religious organization that manages more than 300 health centers over the world. In 2022, the center has 333 beds and 15 operating rooms. It employs more than 2.800 professionals and attends 3.069 births, 17.184 hospitalizations, 5.210 major ambulatory surgery, and 15.329 surgeries are performed. Hospital Sant Joan de Deu is the largest children's hospital in Spain, one of the top5 in Europe, along with Great Ormond Street (London), Hôpital Necker Enfants Malades (Paris) and Ospedale Meyer (Florence), and the reference point in Health 2.0 in Spain. Since 2009 the hospital is associated with the National Association of Children's Hospitals and Related Institutions (NACHRI), a prestigious organization of children's hospitals working to promote health and access to health care for children, and has over 200 members in the United States, Australia, Canada, Italy, Mexico and Puerto Rico.

Inbrain Neuroelectronics is a Neuroelectronics company that specializes in high density and high resolution graphene intelligent neural systems for central and peripheral neuroelectronic applications, with FDA breakthrough Designation.

INMUNOTEK is a pharma company which researches, develops, manufactures and distributes therapeutic vaccines in the fields of allergy, infectious diseases and cancer. In addition, the company develops, manufactures and sells medical devices. INMUNOTEK was founded in 1992 with the mission of improving the quality of life of patients and providing value to healthcare professionals, by creating innovative, safe and effective products. INMUNOTEK's products are sold in both Spain and in more than 50 other countries around the world through our subsidiaries, sales offices and exclusive distributors. Our two production centres are based in the towns of San Sebastián de los Reyes and Alcalá de Henares (Madrid, Spain).

InnoUp is a clinical-stage nanotechnology company focused on developing safer and more effective treatments for Food Allergies, Oncology, and Vaccines. We have developed a new drug encapsulation platform currently being tested in different clinical and pre-clinical programs. INP20 - Oral Peanut Allergy Vaccine: Phase I INP12 - Low-toxicity Paclitaxel oral chemotherapy for Breast Cancer: Phase I INP30 - Oral Vaccine Infectious Diseases: pre-clinical Our encapsulation platform is based on biocompatible nanoparticles that allow all types of payloads (drugs, proteins, RNA, and DNA). These nanoparticles have been engineered to increase bio-adhesion capacity to the mucosa, which translates into a need for lower and safer drug doses to achieve a therapeutic effect. Therefore, drugs encapsulated using our platform become more effective and safer. The technology is protected worldwide, including USA and Europe, until 2035. Our short-term business strategy includes starting operations in the US beginning 2022 with the opening of an affiliate in Boston, MA. From there, we will manage the movement to the next phases of our clinical programs (Phase II) in the US. We are already working with the FDA for the pre-IND meeting preparation. We plan to increase our value in the mid-term by building a clinical-stage multi-asset pipeline with expected significant efficacy and safety milestones by 2025. Besides, we plan to build our GMP manufacturing facility to control our manufacturing process fully. We expect it to be fully operative by 2025. We are actively working on raising money to cover the following steps and, we are open to considering all types of investment. In parallel, we are also actively seeking licensing partners interested in our products.

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers`​ needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

Oncovision is a healthcare technology company that specializes in medical imaging for cancer detection.

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

Reig Jofre is a Spanish pharmaceutical company founded in 1929 in Barcelona. It is currently led by the third generation of the Reig family and is listed on the Spanish Stock Exchange. The company employs over 1,100 people and operates in more than 70 countries through subsidiaries and partnerships. Reig Jofre specializes in pharmaceutical manufacturing, research and development, and commercialization, with production centers located in Barcelona, Toledo, and Sweden. The company offers contract manufacturing services, focusing on sterile injectables, beta-lactam antibiotics, and lyophilized products. It has partnered with Janssen to produce the COVID-19 vaccine and collaborates on various co-development projects. Reig Jofre's product range includes antibiotics, dermatology products utilizing patented technology, hospital injectables, and over-the-counter supplements. Recent developments include the opening of a new manufacturing plant in Barcelona and expansion into the South Korean market.

Rovi is a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Their operations encompass the marketing of both their own and licensed products and the provision of services, such as production, filling and packaging, to other companies.

Sandwalk BioVentures is an end-to-end innovation, strategy, regulatory intelligence and management consulting firm that provides tailored, turnkey solutions to life sciences companies and investors. Specializing in the field of microbiome science, we help food and biopharma start-ups take technologies and products to market by supporting them with corporate, regulatory and commercial affairs, as well as larger corporations and investment firms find meaningful, evidence-based and data-driven market insights to make informed investment and M&A decisions. We are particularly focused on enabling non-EU companies establish, navigate the regulations and market their products in the EU, as well as on supporting EU companies in their regulatory efforts in the US. What makes Sandwalk special is its team’s profound understanding of the science and extensive industry experience. This enables us to go beyond advisory and add value by actively engaging with our partners in the execution of their projects. The "sandwalk" is the path behind Charles Darwin’s Down House near Kent in the UK, where he lived with his family from 1842 until his death in 1882. Down House provided Darwin with the peace and privacy he needed to mature his theories of evolution and natural selection, run his numerous experiments and write most of his works, including his most celebrated On the Origin of Species. The sandwalk was Darwin’s thinking path, around which he made regular circuits several times a day to think about science. "Sandwalk" therefore perfectly captures our essence and way of working: a systematic methodology, based on the thorough assessment of the science, to bring disruptive innovations to life.

Sequentia Biotech, an innovative bioinformatics firm, has been at the forefront of genomics since its establishment in 2013. Renowned for its cutting-edge solutions, Sequentia excels in providing comprehensive bioinformatics and software solutions across a spectrum of fields, including diagnostics, drug discovery, medical and academic research, plant biology, and food technologies. With a remarkable 15 years of experience in bioinformatics and significant investments in Research and Development (R&D), Sequentia has successfully completed over 700 bioinformatics projects. Serving clients in 63 countries, the company has contributed to over 70 publications in esteemed journals, showcasing an impressive H-index of 130. This outstanding track record underscores Sequentia's commitment to excellence. The company's overarching vision is to foster innovation and introduce disruptive technologies in the biotechnology landscape. By leveraging the potential of omics sciences, Sequentia aims to make meaningful contributions to society. Partner with Sequentia as they strive to shape a future where global advancements in biotechnology have a positive and transformative impact on lives.

Nuestro equipo se dedica al desarrollo y comercialización de productos para la salud y el bienestar de las personas, a través de un servicio integral, soluciones innovadoras y productos de máxima calidad bajo normas GMP en: autocuidado, medicina de prescripción, cuidados hospitalarios y servicios especializados para terceros.

Suanfarma founded in 1993, is a B2B life science partner committed to health and innovation by developing, manufacturing, and distributing high quality ingredients for the pharmaceutical industry in an innovative and sustainable way. Suanfarma CDMO offers capacities for fermentation and chemical synthesis projects, providing a “One Stop Shop” service with a solid track record for the development, scaling, manufacturing, & commercialization of an API, either innovative or generic. All facilities comply with the highest existing regulations in the industry. We have a strong network of 12 local offices placed strategically globally, providing services to 400+ customers in 70+ countries.

Universitat de Barcelona is a Higher Education institution that focuses on academic programs and research.

Viralgen is a CDMOfor AAV production that supportslarge-scale manufacturing, fill-finish, and quality control in a GMP-certified environment

We are a biotech company that delivers tailor-made enzymes designed to outperform client's needs. At Zymvol we combine cutting edge technology with top scientific expertise to make  biocatalysis available to everyone. We are a trusted partner that supports our customers in every stage of their bio-journey: from project definition and prioritization to the development and delivery of tailored  enzymes. Our unique approach enables unparalleled accuracy and predictability, along with unprecedented speed. We are the perfect partner for companies aiming to maximize their return on investment and meet their timelines in biocatalysis development. Take your innovation to new limits. www.zymvol.com info@zymvol.com . . . For more information about our Social Media Data Policy, please visit https://zymvol.com/privacy-policy/